A functional study has demonstrated that activation of the Akt/mammalian target of rapamycin (mTOR) pathway accelerates immune escape by elevating PD-L1 expression, where an mTOR inhibitor in combination with antibody PD-1 reduces tumor growth and regulatory T cells, while increasing the abundance of tumor-infiltrating T cells [33]. This evidence concerns the gene AKT1 and neoplasm.